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Abstract
Introduction Type 2 diabetes mellitus (T2DM) and obesity are both related to increased risk of cardiovascular disease and
mortality. Early atherosclerotic vascular changes can be detected by non-invasive tests like carotid artery intima-media thickness
(cIMT) and pulse wave velocity (PWV). Both cIMTand PWVare significantly impaired in T2DM patients and in obese patients,
but the additional effect of T2DM on these vascular measurements in obese subjects has not been evaluated.
Methods Two hundred morbidly obese patients with or without T2DM were enrolled in a prospective cohort study and
underwent extensive laboratory testing, including cIMT and PWV measurements. The cohort was divided into a group with
and a group without T2DM.
Results Within this cohort, 43 patients (21.5%) were diagnosed with T2DM. These patients were older and had more often (a
history of) hypertension as compared to patients without T2DM. HbA1c levels were significantly increased, while LDL choles-
terol was significantly lower and the use of statins higher than in non-diabetic participants. cIMT and PWV were significantly
increased in subjects suffering from T2DM. The variability in cIMTand PWVwas related to differences in age and systolic blood
pressure, but not to the presence of T2DM.
Conclusion While T2DM negatively affects the vasculature in morbid obesity, hypertension and age seem to be the major risk
factors, independent from the presence of T2DM.
Clinical Trial Registration Dutch Trial Register NTR5172.
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Introduction
Type 2 diabetes mellitus (T2DM) is a growing chronic
health problem worldwide and its microvascular and
macrovascular complications cause significant morbidity
and mortality [1]. T2DM is associated with atherosclerosis
[2] and a major risk factor for cardiovascular disease (CVD)
[3, 4]. Atherogenic dyslipidemia is a key factor linking
T2DM to CVD and includes reduced levels of high-
density lipoprotein cholesterol (HDL-C) and increased
levels of triglycerides (TG) and small dense low-density
lipoprotein cholesterol (LDL-C) [3]. LDL-C-lowering ther-
apy can modify the cardiovascular risk in adults suffering
from T2DM, although the risk of CVD remains higher than
in non-diabetic adults [3]. Both the onset and the progres-
sion of atherosclerosis are more rapid in T2DM patients [1].
In addition, the disease may cause premature aging of the
cardiovascular system [5].
Vascular health can be easily monitored by measuring
carotid artery intima-media thickness (cIMT) using carotid
ultrasound. cIMT is an easy and non-invasive method for the
detection of structural signs of carotid atherosclerosis,
which is a significant indicator of subclinical atherosclerosis
and of future cardiovascular disease [1, 3, 6–8]. Close asso-
ciations have been seen between cIMT and conventional
cardiovascular risk factors, such as smoking status, hyper-
tension, and dyslipidemia [8, 9]. Patients suffering from
T2DM are also known to have an increased cIMT in com-
parison to non-diabetic controls [8] and the presence of
T2DM increases the likelihood of early carotid atheroscle-
rosis [9]. Both hyperglycemia and hyperinsulinemia are as-
sociated with an increased risk of atherosclerotic cardiovas-
cular disease, and changes in cIMT are correlated with
changes in fasting plasma glucose, HbA1c, and insulin
levels [1, 9].
Another measure for vascular health is arterial stiffness,
which is an independent risk factor for cardiovascular dis-
ease and mortality [3, 4, 10, 11]. The Bgold standard^ mea-
surement for arterial stiffness is the measurement of the
pulse wave velocity (PWV) [4, 5]. Subjects suffering from
T2DM are known to have a higher PWV than non-diabetic
subjects [4].
Both, IMT and PWV are also known to be increased in
patients suffering from obesity [4, 9, 12] and obesity is
also strongly associated with cardiovascular risk and the
occurrence of coronary heart disease [4]. Furthermore,
obese subjects are more likely to develop T2DM. It is
unknown whether suffering from T2DM worsens vascu-
lar conditions in morbidly obese subjects. As IMT and
PWV may be used as prospective markers for vascular
disease, we selected these markers to establish the effect
of T2DM on the vascular status in morbidly obese
subjects.
Methods
Study Population
Data of this study are derived from the ASSISI study, a pro-
spective cohort study established between April 2015 and
April 2016 and including 200 patients scheduled for bariatric
surgery within our bariatric clinic. All met the international
IFSO criteria for bariatric surgery [13], i.e., patients with a
BMI of ≥ 40 kg/m2 or patients with a BMI of ≥ 35 kg/m2
and obesity-related comorbidity, aged 18 to 65 years.
Patients with a previous cholecystectomy, with a previous
bariatric procedure, with an acute inflammatory disease within
6 weeks prior to inclusion, or using immune-modulating med-
ication were excluded from this study. All data presented here
were collected at study entry, before bariatric surgery.
The study was approved by the independent Regional
Medical Research Ethics Committee Rotterdam (Maasstad
Hospital , Rotterdam, The Netherlands, ABR No.
NL47891.101.14) and all patients gave written informed con-
sent. The ASSISI study is registered in the Dutch Trial
Register (NTR5172).
Definitions
T2DM was defined as a HbA1c ≥ 48 mmol/mol (6.5%) [14]
and/or previously diagnosed T2DM using glucose lowering
medication. Hypertension was defined by a systolic blood
pressure > 140mmHg and/or the use of antihypertensive med-
ication [15]. Hypercholesterolemia was defined as LDL-C >
2.5 mmol/l and/or the use of lipid-lowering drugs [15].
Baseline Characteristics
Baseline characteristics were obtained during standard preop-
erative screening by the internist prior to bariatric surgery and
included the medical history and current medication [16].
Anthropometric characteristics included height, weight, waist
circumference, and blood pressure.
Laboratory Measurements
Preoperative laboratory testing was carried out in all partici-
pants using non-fasting samples. C-reactive protein (CRP),
glucose, total cholesterol, HDL-C, and triglycerides (TG)
were determined using the DxC analyzer (Beckman Coulter,
Crea, CA, USA). LDL-C values were calculated using the
Friedewald formula. HbA1c was measured using an HPLC
G8 analyzer (Tosoh Bioscience, King of Prussia, PA, USA).
Apo B was determined by rate nephelometry using IMAGE
analyzer (Beckman Coulter).
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Carotid Intima-Media Thickness
Carotid intima-media thickness (cIMT) measurements were
performed according to the consensus guidelines for carotid
ultrasound for CVD risk assessment as described previously
[17]. The measurement was carried out using the ART-LAB
(Esaote, Italy) by a trained and experienced sonographer, who
was unaware of the patient’s medical history. Ultrasound
scans were performed with the patients lying in a supine po-
sition with the head resting comfortably and the neck slightly
hyperextended and rotated in the opposite direction of the
probe. The ultrasound images were obtained from the distal
1 cm of the far wall of each common carotid artery (CCA)
using B-mode ultrasound producing two echogenic lines.
These lines represent the combined thickness of the intimal
and medial layers of the arterial wall. Each CCAwas imaged
in three different projections: CCA right side 90-120-150 and
CCA left side 210-240-270 degrees. The segments were mea-
sured semi-automated in triplicate.
Pulse Wave Velocity
Pulse wave velocity (PWV) measurements were carried out
using the Mobil-O-Graph (I.E.M, Germany) as previously de-
scribed [18]. The Mobil-O-Graph uses an inflatable cuff to
measure the PWV. The cuff was placed on the patient’s bare
left upper arm. Triplicate manual measurements were per-
formed. PWV was calculated by the provided software and
was expressed in meter per second.
Statistical Analysis
All analyses were performed using SPSS (PASW) 18.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
Data are given as mean ± standard deviations. Skewed
variables are given in median and interquartile range (IQR).
Categorical data were described in absolute numbers and per-
centages. Differences between subjects with and without
T2DM were analyzed using independent t tests, chi-square
tests, Fisher’s exact tests, and independent sample Mann-
Whitney U tests. For statistical analysis, cIMT was defined
as the mean of the six individual measurements, as described
above, and PWV was defined as the mean of three individual
measurements. Systolic and diastolic blood pressures were
integrated in the mean arterial pressure (MAP), which is the
sum of one-third systolic blood pressure and two-third diastol-
ic blood pressure.
The association between IMT and PWV, both intermedi-
ate measures of subclinical atherosclerosis, with T2DM
was evaluated with univariate linear regression analysis.
To evaluate the effects of both the occurrence of T2DM
and the severity of dysregulation of glucose homeostasis,
linear regression analyses were performed using both the
previously described definition of T2DM and the HbA1c
level. In further analyses, covariables included gender, age,
smoking status, BMI, waist circumference, TG, HDL-C,
LDL-C, CRP, and MAP. Correlations between covariables
(multicollinearity) were checked for confounding and inter-
action effects using stratified analysis. Within the regres-
sion models of T2DM and HbA1c on both IMT and PWV, a
significant interaction effect was observed between HDL-C
and TG, while gender was a significant confounder. Other
confounding factors were ignored in the analyses for hav-
ing a low correlation (< 0.30) or small impact on the out-
come measures. After stratification for gender, the associa-
tions of both T2DM and HbA1c level on cIMT and PWV
were evaluated with multivariable linear regression analy-
sis (model: backward stepwise). The following variables
were entered into the models: gender, age, smoking status,
waist circumference, TG, HDL-C, LDL-C, CRP, HDL-C ×
TG, and MAP. Results of these models were reported as B
coefficients with 95% confidence intervals. Goodness of fit
was evaluated with the adjusted R2. A p value < 0.05 (two-
sided) was considered a statistically significant difference.
Results
The total cohort included 200 patients, 52 men and 148 wom-
en, with a mean age of 41 (± 11.8) years and a mean BMI of
42.7 (± 5.2) kg/m2. Within this cohort, 43 patients (21.5%)
were diagnosed with T2DM. T2DM patients were older and
suffered more frequently from hypertension. In addition, these
patients had more frequently a history of myocardial infarc-
tion. While mean HbA1c values were significantly increased
in diabetes patients, their LDL-C levels were significantly
lower than those in non-diabetics. Diabetic patients were more
frequently treated with lipid-lowering drugs and antihyperten-
sive drugs. Of all diabetic patients, 35 patients (81.4%) were
treated with glucose-lowering drugs; 13 patients received
monotherapy with metformin, 8 received a combination of
insulin and metformin, 10 received a combination of metfor-
min with another oral glucose lowering drug, and 4 received
another treatment. Additional characteristics are displayed in
Table 1.
The median cIMT was significantly increased in patients
suffering from T2DM, when compared to non-diabetics
(0.576 mm (IQR 0.531–0.726) and 0.540 mm (IQR 0.481–
0.634), respectively, p = 0.016). The median PWV was also
significantly higher in diabetic patients compared to non-
diabetics (7.6 m/s (IQR 6.9–8.4) and 6.8 m/s (IQR 5.9–8.0),
respectively, p = 0.005) (Fig. 1).
Univariate linear regression showed that the presence of
T2DM was associated with an increased IMT (crude beta
0.048, adjusted R2 0.021, p = 0.033). Additionally, higher
HbA1c levels were associated with an increased cIMT
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(crude beta 0.001, adjusted R2 0.019, p = 0.041). In a multi-
ple regression analysis, both T2DM and HbA1c did not con-
tribute to the cIMTafter stratification for gender and adjusted
for age, LDL-C, HDL-C, and MAP. The other parameters
included in the analysis did not have any significant effect
on the cIMT.
Table 1 Baseline characteristics
Number Non-T2DM T2DM p value
157 43
Age (years) 39.8 (±12.1) 47.4 (±8.3) p < 0.001a
Female gender 123 (78.3%) 25 (58.1%) p = 0.007b
Medical history (n, %)
Hypertension 77 (49.0%) 31 (72.1%) p = 0.007b
Hypercholesterolemia 124 (79.0%) 34 (79.1%) p = 0.990b
Stroke 3 (1.9%) 2 (4.7%) p = 0.293c
Myocardial infarction 2 (1.3%) 4 (9.3%) p = 0.020c
Medication use (n, %)
Lipid-lowering agents 10 (6.4%) 21 (48.8%) p < 0.001b
Antihypertensive agents 38 (24.2%) 27 (62.8%) p < 0.001b
Smoking habit (n, %) p = 0.861b
No 68 (43.3%) 19 (44.2%)
Former smoker 50 (31.8%) 12 (27.9%)
Yes 39 (24.8%) 12 (27.9%)
BMI (kg/m2) 42.7 (±5.2) 42.7 (±5.2) p = 0.990a
Waist circumference (cm) 129 (±12.9) 132 (±13.5) p = 0.102a
Systolic blood pressure (mmHg) 138 (±19) 143 (±19) p = 0.143a
Diastolic blood pressure (mmHg) 81 (±10) 82 (±11) p = 0.671a
HbA1c (mmol/mol) 38 (±4) 61 (±17) p < 0.001a
Triglycerides (mmol/l) 1.70 (1.13–2.44) 1.96 (1.26–2.93) p = 0.073d
LDL cholesterol (mmol/l) 3.3 (±0.9) 2.5 (±0.9) p < 0.001a
HDL cholesterol (mmol/l) 1.2 (±0.3) 1.2 (±0.3) p = 0.699a
Apo B (g/l) 1.16 (±0.30) 1.00 (±0.25) p = 0.002a
Lipoprotein(a) (mg/l) 196 (80–568) 126 (43–361) p = 0.201d
CRP (mg/l) 5 (3–10) 6 (3–12) p = 0.577d
Leukocytes (109/l) 8.5 (±2.3) 9.3 (±3.0) p = 0.082a
Data are given as mean ± SD, percentage, or median (IQR)
a Independent Student’s t test
b Chi-square test
c Fisher’s exact
d Independent samples Mann-Whitney U test
Fig. 1 Median intima-media thickness (a) and pulse wave velocity (b) in morbidly obese patients with and without type 2 diabetes mellitus
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Using univariate analysis, T2DM was associated with in-
creased PWV (crude beta 0.685, adjusted R2 0.039, p =
0.007). Furthermore, HbA1c levels were also associated with
an increased PWV (crude beta 0.023, adjusted R2 0.043, p =
0.005). In the multivariable analysis, stratified for gender and
after adjustment for age, waist circumference, and MAP,
T2DM was not associated with increased PWV. HbA1c
tended to show a small contribution to PWV in men only
(Table 2).
Discussion
Vascular disease as measured by cIMT and PWV is signifi-
cantly worse in morbidly obese subjects suffering from
T2DM, in comparison to their non-diabetic counterparts.
This is in line with previously described differences in non-
obese subjects [4, 8]. Our data suggest that the presence of
T2DM is not a significant contributor to the levels of IMTand
PWV within the morbidly obese subjects after adjustment for
age, blood pressure, and lipid profile. PWV was mainly deter-
mined by differences in gender, age, waist circumference, and
blood pressure.
cIMTand PWV values are increased in both T2DM [8] and
obesity [4, 9, 12]. However, the impact of having T2DM in a
morbidly obese population on subclinical atherosclerosis has
not been described before. Our study suggests that patients
with T2DM and morbid obesity have a significantly impaired
vascular function, compared to their non-diabetic obese coun-
terparts. However, it should be noted that other cardiovascular
risk factors, linked to T2DM, may have a greater impact on
vascular function, than T2DM itself. The consequence of our
study is that in subjects with morbid obesity and T2DM, one
should consider more strict targets of conventional cardiovas-
cular risk factors.
In general, it is well known that cIMT is mainly influenced
by age and gender in which men and elderly people have an
increased cIMTwhen compared to women and young subjects
[19–23]. In terms of classic cardiovascular risk factors, blood
pressure is the main contributor to increased cIMT. Blood
pressure influences cIMT, for example in young healthy sub-
jects [20, 23, 24], in lean subjects suffering from T2DM [25],
and in elderly patients with cardiovascular risk factors [21].
Additionally, a decrease in blood pressure, for example by
administering antihypertensive drugs, can provide a decrease
in measured cIMT [26]. The second important cardiovascular
risk factor to influence cIMT is dyslipidemia [20–22] and
intensive lipid-lowering therapy can also positively influence
IMT [26–28], although this effect was not observed in diabetic
subjects [29]. The results in these non-obese study populations
are in agreement with the results in our study. Smoking habit
is also thought to influence cIMT in different populations
[20–23], but this association was not observed in our morbidly
obese subjects.
The determinants of arterial stiffness, measured as the
pulse wave velocity, have been less well studied compared
to cIMT. In healthy middle-aged and elderly subjects, not
suffering from T2DM or CVD, PWV is mainly determined
by age, blood pressure, and waist circumference [30], which
is in accordance with the results in our morbidly obese pop-
ulation. Fasting glucose levels are thought to have a modest
impact on PWV and only when diabetic and cardiovascular
patients are included in the study group [30]. Additionally,
both HbA1c [25] and TG [24] levels are thought to play a
role in the development of arterial stiffness, although that
effect is only seen in selected subjects and cannot be
Table 2 Impact of HbA1c levels
on pulse wave velocity (PWV).
The impact of HbA1c level on
PWVwas evaluated withmultiple
linear regression analysis
(backward stepwise analysis)
Parameter PWV
Male Female
Adj. B coefficient (95% CI) p value Adj. B coefficient (95% CI) p value
Constant 0.714 (− 0.567; 1.996)
p = 0.-
265
− 1.086 (−2.628; 0.457)
p = 0.-
166
HbA1c 0.007 (0.000; 0.014)
p = 0.-
060
– –
Age 0.082 (0.070; 0.095)
p < 0.-
001
0.085 (0.075; 0.096)
p < 0.-
001
Waist circumference – – 0.016 (0.007; 0.025)
p = 0.-
001
Mean arterial pressure 0.026 (0.014; 0.038)
p < 0.-
001
0.027 (0.016; 0.037)
p < 0.-
001
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confirmed in all studies or patient groups. Both parameters
were no major determinant of PWV within our morbidly
obese study population.
Obesity is both a major and modifiable risk factor for the
development of metabolic and cardiovascular disease [12].
Weight loss can be an important pillar in the prevention strat-
egy for cardiovascular events. For example, bariatric surgery
can significantly reduce cardiovascular morbidity and mortal-
ity. One study showed that cIMT values were significantly
decreased 1 year after bariatric surgery [31]. An interesting
finding in the current study is the fact that the degree of obe-
sity, in terms of both BMI and waist circumference, did not
influence the value of cIMT or PWV. It can be suggested that
being morbidly obese indeed increases the values of PWVand
cIMT, but that the level of obesity does not really matter once
a certain BMI threshold is surpassed (ceiling effect). A certain
ceiling effect was previously described for markers of dyslip-
idemia [32, 33] and may be true for other cardiovascular risk
factors or vascular outcome measures, such as cIMT and
PWV. Consequently, once morbid obesity is a fact, further
increment of body weight may not cause further deterioration
of subclinical atherosclerosis.
When analyzing the impact of diabetes on cIMT or vascu-
lar function, differences in cardiovascular risk management
between diabetics and non-diabetics can affect the results.
For example, one important pillar of the treatment for type 2
diabetes is the reduction of diabetic dyslipidemia with pre-
scription of statins. Within our morbidly obese population,
diabetic patients were more likely to use statins and therefore
their mean LDL cholesterol level was significantly lower than
that in the non-diabetic group. The differences in cIMT and
PWV between diabetics and non-diabetics may be limited due
to the extensive use of statins in diabetics. However, a previ-
ous study showed that statin use does not influence cIMT in
diabetic patients without previous cardiovascular disease [29]
and only aggressive treatment goals, such as LDL-cholesterol
≤ 70 mg/dl, can influence the progression of cIMT [34].
Another important target in the treatment of diabetic patients
is the prevention of micro- and macrovascular complications
by administration of antihypertensive drugs. Within our co-
hort, the diabetic patients were more likely to be diagnosed
with hypertension and to be treated with antihypertensive
drugs. Diabetic patients with hypertension are known to have
increased cIMT values and increased cIMT progression over
time [35, 36]. Even though the actual value of systolic and
diastolic blood pressures was not significantly different be-
tween the diabetic and non-diabetic subjects in our cohort, it
was previously shown that treatment with antihypertensive
drugs had a positive influence on cIMT and progression of
cIMT, independent of the level of blood pressure [35].
Therefore, the effect of type 2 diabetes on cIMT in this study
may be limited due to the excessive use of antihypertensive
agents within this group.
In conclusion, although T2DM negatively affects the vas-
culature in morbid obesity, age and hypertension seem to be
the main risk factors independent from the presence of T2DM.
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